Dementia — Clinical Documentation Guide (2026)

🔍 Definition

Dementia is a clinical syndrome characterized by acquired, progressive deterioration in cognitive function — including memory, language, problem-solving, executive function, and behavior — severe enough to interfere with daily activities and social or occupational functioning. It is not a single disease but a clinical phenotype caused by multiple underlying pathological processes. Per CMS ICD-10-CM FY2026 guidelines, dementia is coded using a structured hierarchy that combines etiology, severity, and behavioral disturbance into a single highly specific code combination.

The major subtypes encountered in clinical coding include: Alzheimer's disease dementia (most common, ~60–70% of cases), vascular dementia (~15–20%), dementia with Lewy bodies (~5–10%), frontotemporal dementia (FTD/Pick's disease) (~5–10%), and dementia due to other medical conditions (Parkinson's disease, Huntington's disease, HIV, TBI, Creutzfeldt-Jakob disease, and others). Accurate documentation and coding of the underlying etiology, severity level, and any behavioral or neuropsychiatric disturbances are essential for CMS-HCC v28 risk adjustment and for capturing the correct HCC category (HCC 124 vs. HCC 125).

🗂️ Alternative Terminology

The following table identifies formal clinical and lay terminology used in documentation for dementia spectrum conditions. Coders must recognize all variants to ensure accurate code assignment.

🩺 Signs & Symptoms

Clinical documentation should capture both cognitive and neuropsychiatric/behavioral features, as the latter directly affect ICD-10-CM code selection and HCC assignment.

Cognitive Symptoms

• Memory impairment: Episodic memory loss (recent > remote), difficulty learning new information, forgetting appointments, names, or recent events
• Language dysfunction: Word-finding difficulty, aphasia, reduced vocabulary, circumlocution
• Executive dysfunction: Impaired planning, sequencing, abstract reasoning, judgment
• Visuospatial impairment: Getting lost in familiar environments, difficulty with spatial tasks (Alzheimer's, DLB)
• Attention/concentration deficits: Especially prominent in vascular and Lewy body dementia

Behavioral and Neuropsychiatric Symptoms (BPSD) — Code Triggers

• Agitation/aggression: Verbal or physical agitation, combativeness, resistiveness to care → 6th character "1" or "11"
• Psychotic disturbance: Visual/auditory hallucinations, paranoid delusions, misidentification syndromes → 6th character "2"
• Mood disturbance: Depression, emotional lability, apathy, dysphoria → 6th character "3"
• Anxiety disturbance: Generalized anxiety, sundowning, restlessness → 6th character "4"
• Sleep disturbance: REM sleep behavior disorder (especially DLB), insomnia, hypersomnia
• Wandering: Elopement behavior, getting lost

Neurological Signs by Subtype

• Alzheimer's: Gradual onset, symmetric cortical atrophy; anosmia, myoclonus (late)
• Vascular: Stepwise decline, focal neurological deficits, history of stroke/TIA/hypertension
• Lewy body: Fluctuating cognition, visual hallucinations, parkinsonism, REM sleep behavior disorder (core features)
• FTD/Pick's: Personality change, disinhibition, hyperorality, semantic/syntactic language loss
• Parkinson's dementia: Motor features precede cognitive decline by ≥1 year

🧭 Differential Diagnosis

Coders and CDI specialists must be alert to conditions that may mimic or co-exist with dementia, as each has distinct code assignments and clinical implications.

📋 Clinical Indicators for Coders/CDI

The following table summarizes key documentation elements that support specific dementia code assignments. CDI specialists should audit for these indicators in every dementia encounter.

🦴 Anatomy & Pathophysiology

Understanding the pathophysiological basis of dementia subtypes helps coders and CDI specialists identify documentation clues that support specific code selection.

Alzheimer’s Disease

Alzheimer's disease (AD) is characterized by extracellular amyloid-beta (Aβ) plaques and intraneuronal neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein. Neurodegeneration begins in the entorhinal cortex and hippocampus (explaining early episodic memory loss) before spreading to association cortices. Per National Institute on Aging (NIA), AD affects approximately 6.7 million Americans age 65 and older. The 2023 FDA approvals of lecanemab (Leqembi) and 2024 approval of donanemab (Kisunla) — both anti-amyloid monoclonal antibodies — represent the first disease-modifying therapies for early AD, targeting Aβ clearance.

Vascular Dementia

Vascular cognitive impairment arises from cerebrovascular disease — including large-vessel strokes, small-vessel (lacunar) disease, and white matter hyperintensities. The mechanism involves ischemic injury to cortical and subcortical networks essential for cognition, particularly frontal-subcortical circuits. Risk factors (hypertension, diabetes, atrial fibrillation, dyslipidemia) are the same as for stroke. Unlike Alzheimer's, vascular dementia often presents with stepwise decline rather than gradual progression.

Lewy Body Dementia

Dementia with Lewy bodies (DLB) and Parkinson's disease dementia (PDD) share the pathological substrate of alpha-synuclein aggregates (Lewy bodies) distributed in cortical and limbic regions. DLB is distinguished by dementia onset concurrent with or preceding motor features; in PDD, motor symptoms precede cognitive decline by ≥1 year. The characteristic fluctuating cognition and visual hallucinations result from cholinergic deficits and limbic involvement. REM sleep behavior disorder (RBD) is an early biomarker. ICD-10-CM uses G31.83 for Lewy body disease, coded with F02.8x for the dementia manifestation.

Frontotemporal Dementia (FTD / Pick’s Disease)

FTD encompasses a heterogeneous group of neurodegenerative disorders with selective frontal and temporal lobe atrophy. Pathologically, FTD is associated with tau (Pick bodies in Pick's disease; MAPT mutations), TDP-43, or FUS protein inclusions. The behavioral variant (bvFTD) presents with personality change, disinhibition, and executive dysfunction; language variants present as progressive aphasia. G31.01 (Pick's disease) and G31.09 (other FTD) are coded with F02.8x for the dementia manifestation.

Severity Staging Correlates

The FY2026 severity subcategories (A=mild, B=moderate, C=severe) align with validated staging tools: the Alzheimer's Association staging, CDR (Clinical Dementia Rating scale), and FAST (Functional Assessment Staging Test). CDR 0.5–1 corresponds to mild; CDR 2 to moderate; CDR 3 to severe. Documentation of specific CDR, MMSE, or MoCA scores supports severity axis assignment and defends against retrospective audit challenges.

💊 Medication Impact / Treatment

Pharmacological and non-pharmacological management of dementia directly informs code selection, CDI queries, and HCPCS/CPT billing opportunities.

Cholinesterase Inhibitors (AChEIs)

First-line symptomatic therapy for mild-to-moderate Alzheimer's dementia includes donepezil (Aricept — all stages), rivastigmine (Exelon — also for PDD), and galantamine (Razadyne). These agents inhibit acetylcholinesterase, increasing synaptic acetylcholine. All are oral medications billed under Part D via NDC; rivastigmine transdermal patch (HCPCS J3490) may be billed under Part B in select circumstances. Presence of AChEI prescriptions in the medication list is a strong CDI indicator that the clinician has diagnosed and is treating dementia.

NMDA Receptor Antagonist

Memantine (Namenda) is approved for moderate-to-severe Alzheimer's dementia; it may be combined with an AChEI. Memantine is also used off-label in other dementia subtypes. Documentation of memantine use supports severity coding (moderate/severe subcategory — B or C).

Disease-Modifying Anti-Amyloid Therapies (Early AD)

• Lecanemab (Leqembi) — FDA-approved January 2023 (accelerated) and July 2023 (full approval) for early AD (MCI due to AD or mild AD dementia with confirmed amyloid pathology). HCPCS J0173 (lecanemab-irmb) — note: code may be pending; J3490 (unclassified biologic) used when specific J-code not yet assigned. Billed IV infusion. Per FDA approvals database, full approval granted July 2023.
• Donanemab (Kisunla) — FDA-approved July 2024 for early symptomatic AD. HCPCS J3490 or assigned J-code when available. IV infusion; requires amyloid PET or CSF confirmation.

Behavioral/Neuropsychiatric Symptom Management

• Antipsychotics (quetiapine, risperidone, olanzapine — all off-label): for agitation, psychosis; FDA black box warning for use in elderly with dementia (increased mortality risk)
• Antidepressants (SSRIs — sertraline, citalopram; SNRIs): for mood disturbance, anxiety, apathy
• Benzodiazepines (short-term only): for acute agitation; risk of falls, paradoxical agitation
• Melatonin / trazodone: for sleep-wake cycle disturbances
• Pimavanserin (Nuplazid): FDA-approved for Parkinson's disease psychosis; investigational for dementia-related psychosis (DRP)

Non-Pharmacological Interventions

Cognitive stimulation therapy, structured activity programs, caregiver training, and environmental modifications are mainstays of dementia care. Music therapy, reminiscence therapy, and sensory stimulation are evidence-based non-drug approaches for BPSD management per Alzheimer's Association treatment guidelines.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides